Antiretroviral News and Research

RSS

Mylan receives shareholders' approval for proposed Perrigo acquisition

Mylan N.V. today announced that its shareholders have approved Mylan's proposed acquisition of Perrigo Company plc and the related issuance of Mylan ordinary shares to Perrigo's shareholders at an extraordinary general meeting of shareholders held today.

28 Aug 2015

New studies evaluate viral suppression rate of HIV-infected pregnant women at delivery

Pregnancy could be a turning point for HIV-infected women, when they have the opportunity to manage their infection, prevent transmission to their new baby and enter a long-term pattern of maintenance of HIV care after giving birth--but most HIV-infected women aren't getting that chance.

26 Aug 2015

Mylan releases generic version of Zosyn Injection in the U.S.

Mylan N.V. today announced the U.S. launch of Piperacillin and Tazobactam for Injection USP, 3.375g Single-dose Vials, which is the generic version of Pfizer's Zosyn Injection.

26 Aug 2015

Mylan sued in connection with ANDA filing for generic version of Zytiga

Mylan N.V. today confirmed that the company has been sued by BTG International Ltd., Janssen Biotech, Inc., Janssen Oncology, Inc., and Janssen Research & Development, LLC in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration for Abiraterone Acetate Tablets, 250 mg.

18 Aug 2015

Ontario nearing ambitious UN targets for ending AIDS epidemics

A new study suggests Ontario is nearing ambitious United Nations targets for ending the AIDS epidemics: By 2020, 90 per cent of all people living with HIV should know their HIV status, 90 per cent of all people diagnosed with HIV are receiving sustained antiretroviral drug therapy and 90 per cent of people on ART have a very low or undetectable levels of the virus.

14 Aug 2015

PHIV children may lack immunity against measles, mumps, and rubella despite vaccination

Between one-third and one-half of individuals in the United States who were infected with HIV around the time of birth may not have sufficient immunity to ward off measles, mumps, and rubella--even though they may have been vaccinated against these diseases.

14 Aug 2015

Mylan announces launch of Lidocaine Patch 5% in the U.S.

Mylan N.V. today announced the U.S. launch of its Lidocaine Patch 5%, which is the generic version of Endo Pharmaceutical's Lidoderm. Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for relief of pain associated with post-herpetic neuralgia.

10 Aug 2015

Mylan announces launch of Esomeprazole Magnesium Delayed-release Capsules USP in U.S.

Mylan N.V. today announced the U.S. launch of Esomeprazole Magnesium Delayed-release Capsules USP, 20 mg and 40 mg, which is the generic version of AstraZeneca's Nexium.

6 Aug 2015

Northwestern gets $17.5 million NIH grant to invent, develop implantable drug delivery system for HIV prevention

Northwestern Medicine scientists have received a five-year, $17.5 million grant from the National Institutes of Health for an interdisciplinary project that aims to invent, develop and test an implantable drug delivery system to protect high-risk individuals from HIV infection for up to a year at a time.

4 Aug 2015

Pitt investigators to lead $5 million initiative to monitor resistance to HIV prevention drugs in sub-Saharan Africa

Infectious diseases researchers from the University of Pittsburgh School of Medicine are leading a five-year, $5 million initiative to monitor drug resistance during the rollout of HIV prevention drugs in sub-Saharan Africa.

4 Aug 2015

Mylan receives regulatory clearance from European Commission for proposed acquisition of Perrigo

Mylan N.V. today announced that it received regulatory clearance from the European Commission under the European Union Merger Regulation (EUMR) for its proposed acquisition of Perrigo Company plc.

29 Jul 2015

Screening for HIV in pregnancy eliminates vertical transmission

Canada has almost eliminated mother-to-child HIV transmission, known as vertical transmission, in recent years by ensuring that all women have the opportunity to be screened for HIV in pregnancy and that women with the disease receive treatment before giving birth.

23 Jul 2015

Study: Cash to stay in school did not reduce HIV risk among young women in South Africa

A Phase III, individually randomized trial has found conditional cash transfers for school attendance did not reduce the risk of HIV among high-school aged women in South Africa, investigators from the HIV Prevention Trials Network (HPTN) reported today at the 8th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention in Vancouver, Canada.

22 Jul 2015

InnaVirVax presents positive results of IVVAC-3S/P1 study at International AIDS Society Conference

InnaVirVax, a biopharmaceutical company specialized in research and development of therapeutic and diagnostic solutions for major infectious and chronic diseases, today announced the overall results of its Phase I/IIa clinical study of its VAC-3S immunotherapy, which is currently in development.

22 Jul 2015

Early antiretroviral treatment prevents AIDS- and non-AIDS-related diseases in HIV-infected people

Starting antiretroviral therapy early not only prevents serious AIDS-related diseases, but also prevents the onset of cancer, cardiovascular disease, and other non-AIDS-related diseases in HIV-infected people, according to a new analysis of data from the Strategic Timing of AntiRetroviral Treatment (START) study, the first large-scale randomized clinical trial to establish that earlier antiretroviral treatment benefits all HIV-infected individuals.

22 Jul 2015

Beckman Coulter announces expansion of Cellular Accessible Retroviral Evaluation Systems Initiative at International AIDS Society 2015

Beckman Coulter Life Sciences today announces an expansion of its CARES Initiative at the 2015 International AIDS Society (IAS) Conference.

From Beckman Coulter Life Sciences - Flow Cytometry 21 Jul 2015

Phase II open-label study demonstrates that high-risk populations adhere well to daily regimen of PrEP

Results from HPTN 067, a Phase II, randomized, open-label study, demonstrate most study participants had higher coverage of sex events and better adherence when they were assigned to the daily dosing arm, investigators from the HIV Prevention Trials Network (HPTN) reported today at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Vancouver, Canada.

21 Jul 2015

Study findings provide basis for potential development of new methods to control HIV infection

Lower levels of cholesterol in certain immune cells--a result of enhanced cholesterol metabolism within those cells--may help explain why some HIV-infected people are able to naturally control disease progression, according to research that will be presented in a poster at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015) in Vancouver, Canada, and the pre-conference 2015 Towards an HIV Cure Symposium.

20 Jul 2015

Canadian researchers discover how HIV evades the body's antiviral responses

A Canadian research team at the IRCM in Montreal, led by molecular virologist Eric A. Cohen, PhD, made a significant discovery on how HIV escapes the body's antiviral responses. The team uncovered how an HIV viral protein known as Vpu tricks the immune system by using its own regulatory process to evade the host's first line of defence.

16 Jul 2015

Mylan announces launch of generic Namenda Tablets in U.S.

Mylan N.V. today announced the U.S. launch of Memantine Hydrochloride Tablets USP, 5 mg and 10 mg, which is the generic version of Forest's Namenda Tablets.

14 Jul 2015

Antiretroviral News and Research

Mylan receives shareholders' approval for proposed Perrigo acquisition

New studies evaluate viral suppression rate of HIV-infected pregnant women at delivery

Mylan releases generic version of Zosyn Injection in the U.S.

Mylan sued in connection with ANDA filing for generic version of Zytiga

Ontario nearing ambitious UN targets for ending AIDS epidemics

PHIV children may lack immunity against measles, mumps, and rubella despite vaccination

Mylan announces launch of Lidocaine Patch 5% in the U.S.

Mylan announces launch of Esomeprazole Magnesium Delayed-release Capsules USP in U.S.

Northwestern gets $17.5 million NIH grant to invent, develop implantable drug delivery system for HIV prevention

Pitt investigators to lead $5 million initiative to monitor resistance to HIV prevention drugs in sub-Saharan Africa

Mylan receives regulatory clearance from European Commission for proposed acquisition of Perrigo

Screening for HIV in pregnancy eliminates vertical transmission

Study: Cash to stay in school did not reduce HIV risk among young women in South Africa

InnaVirVax presents positive results of IVVAC-3S/P1 study at International AIDS Society Conference

Early antiretroviral treatment prevents AIDS- and non-AIDS-related diseases in HIV-infected people

Beckman Coulter announces expansion of Cellular Accessible Retroviral Evaluation Systems Initiative at International AIDS Society 2015

Phase II open-label study demonstrates that high-risk populations adhere well to daily regimen of PrEP

Study findings provide basis for potential development of new methods to control HIV infection

Canadian researchers discover how HIV evades the body's antiviral responses

Mylan announces launch of generic Namenda Tablets in U.S.

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News